Products billed under this code include Tecartus.
Payment limit per UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR POSITIVE VIABLE T CELLS, by effective quarter, 2Q23 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Tecartus | Gilead Sciences, Inc. | 71287-0219-01 | 1 | $532,352.741 |
| Tecartus | Gilead Sciences, Inc. | 71287-0220-01 | 1 | $532,352.741 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $532,352.741 | +$22,248.822 | UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR POSITIVE VIABLE T CELLS | Brexucabtagene car pos t | v1, posted September 17, 2026 |
| 3Q26 | $510,103.919 | +$20,813.318 | UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR POSITIVE VIABLE T CELLS | Brexucabtagene car pos t | v1, posted September 15, 2026 |
| 2Q26 | $489,290.601 | −$159.601 | UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR POSITIVE VIABLE T CELLS | Brexucabtagene car pos t | v1, posted September 15, 2026 |
| 1Q26 | $489,450.202 | +$145.594 | UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR POSITIVE VIABLE T CELLS | Brexucabtagene car pos t | v1, posted September 15, 2026 |
| 4Q25 | $489,304.608 | −$415.392 | UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR POSITIVE VIABLE T CELLS | Brexucabtagene car pos t | v1, posted September 8, 2026 |
| 3Q25 | $489,720.00 | +$320.843 | UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR POSITIVE VIABLE T CELLS | Brexucabtagene car pos t | v1, posted March 10, 2026 |
| 2Q25 | $489,399.157 | +$1,347.647 | UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR POSITIVE VIABLE T CELLS | Brexucabtagene car pos t | v1, posted March 10, 2026 |
| 1Q25 | $488,051.51 | +$27,521.108 | UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR POSITIVE VIABLE T CELLS | Brexucabtagene car pos t | v1, posted December 19, 2025 |
| 4Q24 | $460,530.402 | +$11,090.402 | UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR POSITIVE VIABLE T CELLS | Brexucabtagene car pos t | v1, posted June 11, 2025 |
| 3Q24 | $449,440.00 | $0.00 | UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR POSITIVE VIABLE T CELLS | Brexucabtagene car pos t | v1, posted June 11, 2025 |
| 2Q24 | $449,440.00 | $0.00 | UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR POSITIVE VIABLE T CELLS | Brexucabtagene car pos t | v1, posted March 11, 2025 |
| 1Q24 | $449,440.00 | $0.00 | UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR POSITIVE VIABLE T CELLS | Brexucabtagene car pos t | v1, posted December 19, 2024 |
| 4Q23 | $449,440.00 | $0.00 | UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR POSITIVE VIABLE T CELLS | Brexucabtagene car pos t | v1, posted October 10, 2024 |
| 3Q23 | $449,440.00 | +$687.598 | UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR POSITIVE VIABLE T CELLS | Brexucabtagene car pos t | v1, posted June 5, 2024 |
| 2Q23 | $448,752.402 | – | UP TO 200 MILLION AUTOLOGOUS ANTI-CD19 CAR POSITIVE VIABLE T CELLS | Brexucabtagene car pos t | v1, posted February 23, 2024 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.
